Portal de Periódicos da CAPES

Phototherapy and topical treatments for cutaneous graft vs. host disease in haematopoietic stem cell transplantation patients: a scoping review

2022; Wiley; Volume: 36; Issue: 7 Linguagem: Inglês

10.1111/jdv.18074

1468-3083

Elena Rostagno, Anna Campanati, Nicola Mordini, Chiara Cannici, Marco Cioce, Valentina De Cecco, Emanuela Samarani, Robin Foà, Attilio Olivieri, Stefano Botti,

Immunotherapy and Immune Responses

Abstract Skin is usually the first and most affected organ involved in graft‐versus‐host disease (GvHD), and treatment is still a clinical challenge. Although the need for skin‐directed treatments such as physical treatments and topical medications are generally agreed on, what the gold standard treatment strategy should be remains open to debate. The aim of this scoping review was to synthesize the current knowledge on the topical and physical treatments of cutaneous GvHD in haematopoietic stem cell transplantation patients and to highlight the best evidence available so as to reduce the gap between ‘what is known’ and ‘what is done’ in the clinical practice. Twenty‐eight studies were included in this qualitative synthesis. Photo‐biomodulation with psoralen was not included in this review. Phototherapy (ultraviolet A or B or narrowband B) was the physical treatment most described in the literature in both acute GvHD and chronic GvHD. Topical calcineurin inhibitors such as tacrolimus ointment and pimecrolimus cream as well as corticosteroid creams such as clobetasol and triamcinolone are mainly used in case of chronic GvHD. In all of the studies included in the review, topical treatments were always associated with systemic therapy. None of the topical interventions identified in our review provided strong evidence supporting its use, and the topical approaches seemed to have an adjuvant role in the treatment of cutaneous GvHD.